The potential role of vinflunine in sequential treatment strategies for urothelial carcinoma, in both the perioperative setting and maintenance therapy, will be highlighted below.
Rationale for Perioperative Systematic Therapy in Bladder Cancer
The natural history and evolution of urothelial carcinoma suggests that the study of perioperative systemic therapy may yield benefits (see Table 1 ), [1] [2] [3] [4] [5] [6] [7] [8] [9] because 20-50 % of patients experience distant recurrence, and 5-15 % have locoregional recurrence.
The gold standard for patients with muscle-infiltrating disease is cystectomy. However, when comparing cystectomy series, survival is strictly related to the invasion of the bladder wall (see Table 1 ).
The probability of non-recurring and organ-confined disease is approximately 80-90 %, while in patients with extravesical invasion it drops to 60 % and to 30 % in patients with nodal involvement after cystectomy. These figures explain why perioperative chemotherapy is an attractive option. Based on good responses obtained in advanced disease, chemotherapy is shifting to the neoadjuvant setting.
Long-term results of radical cystectomy in the treatment of invasive bladder cancer were presented by Stein et al. in 1,054 patients.
Increasing tumour stage and nodal involvement were associated with significantly higher recurrence rates and worse overall survival (OS) (p<0.001). Specifically, patients with extravesical disease or lymph node positive (LN+) disease had a higher risk of recurrence compared with patients who had organ-confined disease. The 10-year OS for patients with extravesical bladder tumours was 27 %. In patients with LN+ disease the OS at 10 years was 23 %. Respective recurrence-free values were 47 % and 31 %. 5 These data provide a strong biological rationale for perioperative systemic therapy in bladder cancer.
Neoadjuvant or Adjuvant Therapy in Invasive Bladder Cancer
Several unanswered questions arise when gauging perioperative treatment options and the timing of cystectomy in patients with invasive bladder cancer. For instance, should radical cystectomy be performed without delay or is neoadjuvant chemotherapy a valid strategy?
Should cystectomy be performed regardless of chemotherapy? Should the bladder be preserved and cystectomy be delayed according to chemotherapeutic response? Should adjuvant chemotherapy be administered, and if so, which regimen would be the most suitable?
Neoadjuvant Chemotherapy
Based on the encouraging results obtained with cisplatin combination chemotherapy regimens in patients with advanced, metastatic disease, use of neoadjuvant chemotherapy has been advocated to improve survival in patients with micrometastatic disease, and second, to preserve the bladder. It is thought that therapy may be better tolerated in patients upfront prior to cystectomy. On the other hand, neoadjuvant chemotherapy may make surgery more challenging and increase post-operative complications. A malignancy that is resistant to neoadjuvant chemotherapy may progress due to delay of surgery.
Other disadvantages associated with neoadjuvant chemotherapy include difficulties in assessing response, and the fact that staging is based on clinical rather than pathological criteria. Benefits obtained in some studies are not reproducible. Only meta-analyses allowed to show a survival benefit ranging from 5 to 7 % (see Table 2 ).
Almost all neoadjuvant chemotherapy trials were negative, except for that conducted by the Southwest Oncology Group (SWOG) in 317 patients, which compared methotrexate, vinblastine, doxorubicin and cisplatin 8 These data strongly support the argument that neoadjuvant chemotherapy followed by radical cystectomy should be further investigated as an approach to optimise muscle-invasive bladder cancer treatment.
A subsequent retrospective analysis showed that patients who underwent neoadjuvant chemotherapy and successful surgery, having had more than 10 lymph nodes removed, had a 5-year survival of 81 %, whereas patients who did not receive neoadjuvant chemotherapy and had fewer than 10 lymph nodes removed had a 5-year survival of 39 %. 15 Surgical factors, therefore, have a considerable impact on bladder cancer outcome, and many factors are determinant for survival (see Table 3 ). The quality of surgery cannot be underestimated.
The largest neoadjuvant chemotherapy randomised trial was performed in 976 patients with T2-T4 muscle-invasive N0 urothelial cancer. years), the 6 % survival difference was maintained with neoadjuvant CMV (HR=0.84, 95 % CI 0.72-0.99; p=0.037). The threshold for absolute difference in survival is a point of debate.
A difference of 10 % has been proposed as a minimal threshold for success, 17 which may arbitrarily obscure the benefit conferred by perioperative chemotherapy. Colon cancer literature has, for instance, shown that adjuvant chemotherapy demonstrated a survival improvement with smaller absolute survival differences. 20 Another concern is that many patients are ineligible for cisplatin-based combination adjuvant chemotherapy. There is a concern that toxicity of neoadjuvant chemotherapy could delay surgery, although data from the Medical Research Council/European Organisation for Research and Treatment of Cancer (MRC/EORTC) and SWOG studies suggest that this is not the case. 8, 17 Patients with small pT2 tumours can be cured with surgery alone, and it has been proposed that it may not be in their interest to receive neoadjuvant treatment. Survival data from the SWOG trial argue against this notion, 8 as neoadjuvant chemotherapy-prolonged patient survival with clinical T2 tumours by 2.5 years compared with surgery alone. Furthermore, surgical clinical staging data have shown that lowrisk clinical T2 patients who can be spared chemotherapy cannot be accurately identified by urologists. [21] [22] [23] It has also been argued that patients could receive adjuvant chemotherapy instead of neoadjuvant chemotherapy with a similar survival benefit.
Although plausible, in practice, a third of patients do not receive postoperative chemotherapy following cystectomy, mainly because of poor PS, complications related to surgery, psychological distress, age or patient refusal. Quality of life data would help address the question of whether neoadjuvant therapy may be preferable to adjuvant therapy.
Adjuvant Chemotherapy
The perceived benefits and detriments of adjuvant chemotherapy have also been the centre of debate. The advantages of adjuvant chemotherapy include accurate pathological staging, which facilitates evaluation of patient risk. Chemotherapy can be avoided in low-risk patients, and overtreatment can thus be prevented. Finally, this practice avoids delaying definitive surgery. The main disadvantages are that no in vivo assessment of patients is available, and that many patients are less able to tolerate chemotherapy after surgery.
An ABC meta-analysis showed an absolute survival benefit of 9 % (HR=0.75, 95 % CI 1-16 %; p=0.019) at 3 years in patients who received cisplatin-based therapy, although these data are likely flawed by the poor quality of the trials included. 24 Most adjuvant chemotherapy trials are underpowered, and have included fewer than 100 patients, complicating the drawing of definite conclusions. Data exploring adjuvant chemotherapy have shown that many patients are ineligible for cisplatinbased combination adjuvant chemotherapy after surgery. Once again, the quality of received surgery is essential to optimise patient prognosis. Three recent trials have closed due to poor accrual. Data from a prospective meta-analysis of the EORTC individual patient data will be of interest.
How can Perioperative Chemotherapy Results be Improved?
Suggestions on how to improve outcomes of perioperative chemotherapy include the discovery and use of predictive factors of response, and the use of new drugs and targeted agents. Based on retrospective studies suggesting that urothelial carcinoma patients with altered p53 had worse survival compared with patients who had wild-type p53, a randomised trial evaluating MVAC adjuvant chemotherapy was performed in these patients after cystectomy. 25 Based on p53 status, 521 patients were randomised to receive MVAC for three cycles versus observation. The results of initial studies were not corroborated, and the predictive and prognostic value of p53 status was not confirmed.
The study and validation of predictive factors is likely to be among the most interesting fields in the development of new drugs, because tumour biopsies are available prior to chemotherapy. Studies can be performed before administering chemotherapy (e.g. genomics or proteomics).
Following treatment and radical cystectomy, the mechanism of resistance can for instance be studied in patients with residual tumours who do not respond. pCR can be rapidly determined after surgery, or after three to four cycles of neoadjuvant chemotherapy. Given that pCR is a favourable prognostic factor correlating with long-term outcomes, the efficacy of a systemic regimen is evident early. however, reported that twice as many physicians administered adjuvant chemotherapy compared with neoadjuvant chemotherapy. 27 A phase III trial is planned in the neoadjuvant setting that is going to investigate cisplatin plus gemcitabine versus accelerated MVAC, with the objective of comparing regimens and collecting tissue samples to assess whether efficacy can be predicted. One of the caveats associated with performing this randomised trial is that both arms are experimental. Standard MVAC was initially planned, but accelerated MVAC was chosen because it is better tolerated and may be more active. 28 
Two-tiered Treatment Strategy in the Metastatic Setting
In the metastatic urothelial carcinoma setting, problems include the fact that it is an aggressive disease, which despite being chemosensible, has not been investigated in a large number of randomised controlled trials.
Metastatic urothelial carcinoma affects an elderly population, and is associated with various comorbidities that include reduced renal function.
Von der Maase et al. compared GC versus MVAC in patients with locally advanced or metastatic TCCU (n=405). OS, time to progressive disease, time to treatment failure and response rate were similar in both arms.
However, GC had a better safety and tolerability profile compared with MVAC, 29 which is why most trials use GC as the preferred chemotherapy template for patients with locally advanced and metastatic TCCU.
The median survival of GC or MVAC regimens is about 15 months, although outcomes demonstrate heterogeneity based on the number of prognostic factors (PS <80 % and visceral metastases). 30, 31 Over that last 20 years, treatment objectives in metastatic urothelial carcinoma have been to increase the number of CR and prolong response duration. The therapeutic strategies that have been adopted include evaluation of new combinations (e.g. triplets), sequential therapies, maintenance therapies, new drugs and molecular targeted therapies. 
New Combinations
In investigations of new triplet combinations, the addition of paclitaxel
to GC did not demonstrate a statistical improvement in survival of urothelial carcinoma, nor did dose-dense chemotherapy regimens (see Tables 4 and 5) . [32] [33] [34] [35] [36] [37] Phase III randomised trials have not shown important improvements in OS when investigating regimens other than GC or MVAC (see Table 6 ). 29, 36, [38] [39] [40] [41] [42] [43] Thus, in the field of metastatic urothelial cancer treatment, a plateau has probably been reached, with little improvement in the last 10 years with doublet or triplet combinations. MVAC and GC regimens are firmly established as standard chemotherapies in the first-line setting, and vinflunine is the only approved drug for use after failure of a platinumbased regimen. The role of targeted therapies in the treatment of metastatic bladder cancer is still not known.
Sequential Therapies
Theoretical models suggest that sequential administration of chemotherapy may improve targeting of different cell populations within a tumour. Additionally, administration of two or three sequential drug combinations in high doses may overcome the toxicity associated with simultaneous administration of those agents. For instance, in a phase II trial conducted by Galsky et al., dose-dense doxorubicin plus gemcitabine followed by paclitaxel and carboplatin was given to 25 patients with advanced urothelial carcinoma and renal impairment. 44 Overall response rate was 56% (including 35 % CR) (95 % CI 35-76 %), and median OS was 15 months (95 % CI, 11-30 months). Myelosuppression was the major toxicity, with 28 % G3/4 neutropenia. The 3-year survival was 25 %, and 28 % of patients were disease-free at 45 months. Dose-dense sequential chemotherapy was therefore tolerable and active in these patients.
Prolonged disease-free survival was achieved in a subset of patients with primary unresectable disease or LN+ disease treated with carboplatin-based therapy with or without surgery. 68 % of patients. The authors concluded that the regimen was active but associated with elevated toxicity, which did not appear to be superior to non-sequential regimens. 45 An additional rationale for sequential therapy is that different cell types are present in a given population of tumour cells, 46 and clonal populations may develop when treated with a combination regimen. Administration of sequential therapy may slow the development of subclones.
Maintenance Therapy and Targeted Therapy
Based on vinflunine efficacy following failure of platinum-based chemotherapy, [47] [48] [49] maintenance therapy with vinflunine could be of interest. With the knowledge that resistance occurs over time, 50 the early use of non-cross-resistant treatment regimens could be interesting after first-line platinum-based chemotherapy, because this approach may increase the probability of killing more cancer cells before the development of resistance. In NSCLC, as shown in a recent single-agent meta-analysis of 12 studies in a total of 4,286 patients, 52 patients who had maintenance chemotherapy consistently performed better than patients who were followed by observation alone. Switch maintenance was also shown to be superior to continuation maintenance. 52 On the strength of these maintenance data in NSCLC, two maintenance studies have been initiated in fit TCCU patients not progressing on cisplatin-based chemotherapy. The international JASIMA multicentre in 77 patients will evaluate vinflunine maintenance after four cycles of GC combination. The second maintenance study is the randomised phase II multicentre MAJA Spanish trial in patients (39 per arm) who will be randomised to receive vinflunine+BSC versus BSC alone after six cycles of GC (NCT01529411).
The primary objectives of these studies is PFS. Maintenance trials ought to be designed to measure time to disease progression, for which a randomised design is essential. The MAJA trial is a randomised trial. There may be concerns with patient heterogeneity, because eligible patients were allowed to receive four to six GC treatment cycles prior to randomisation. However, it is an exploratory trial that will help assess the toxicity of switching to a different drug with a separate mechanism of action, and whether maintenance therapy with vinflunine provides some benefit in terms of relapse.
Conclusion
Neoadjuvant chemotherapy is an interesting potential approach in the development of new drugs, and may expedite the development of new agents. A feasibility study evaluating the combination of neoadjuvant cisplatin and vinflunine would be of interest in bladder cancer patients, and the inclusion of a translational component would add value to the analysis, in order to identify biomarkers. The study would naturally involve strict control of the primary tumour, because cystectomy will be delayed in participating subjects. Vinflunine may have a role as frontline neoadjuvant chemotherapy in combination with cisplatin or in nonresponders after cystectomy. In addition to neoadjuvant chemotherapy, there is also a strong rationale for maintenance chemotherapy, and vinflunine may also play a role in this setting. n
